Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review

Michael J Trujillo; Johnson Chen; Jonathan M Rubin; Jing Gao

doi:10.1016/j.clinimag.2021.02.039

Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review

Clin Imaging. 2021 Oct:78:22-34. doi: 10.1016/j.clinimag.2021.02.039. Epub 2021 Mar 10.

Authors

Michael J Trujillo¹, Johnson Chen², Jonathan M Rubin³, Jing Gao⁴

Affiliations

¹ Rocky Vista University, Ivins, UT, USA.
² Weill Cornell Medicine, Cornell University, NY, New York, USA.
³ University of Michigan, Ann Arbor, MI, USA.
⁴ Rocky Vista University, Ivins, UT, USA; Weill Cornell Medicine, Cornell University, NY, New York, USA. Electronic address: [email protected].

PMID: 33721575
DOI: 10.1016/j.clinimag.2021.02.039

Abstract

This review summarizes the current state of non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD). This begins with a brief discussion of blood-based analysis (serum biomarkers) then progresses through various imaging modalities (imaging biomarkers) including magnetic resonance (MR), computed tomography (CT), and ultrasound-based imaging methods. The review concludes with comment on the advantages, disadvantages, and prospects of commercially available modalities and the impact they may have on diagnosis and management of patients with NAFLD.

Keywords: Computed tomography; Hepatic steatosis; MRI; Nonalcoholic fatty liver disease; Ultrasound.

Publication types

Review

MeSH terms

Biomarkers
Humans
Liver / diagnostic imaging
Magnetic Resonance Imaging
Non-alcoholic Fatty Liver Disease* / diagnostic imaging
Ultrasonography

Substances

Biomarkers